TRPM8
Transient receptor potential cation channel subfamily M member 8
As of the edition of 20 October 2026, TRPM8 (transient receptor potential cation channel subfamily M member 8, UniProt Q7Z2W7) has 6 drugs tested at it and 10 companies on the list, 1 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q7Z2W7
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 6
- Disease areas
- Eye; Nervous system; Lungs and airways; Digestive system; Ear, nose and throat; Cancer; Infections; Mouth and teeth
- Registered trials of its drugs
- 75
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 1 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Menthol | Marketed | Phase 4 | none listed |
| Acoltremon | Marketed | Phase 4 | Ends 2030 |
| Elismetrep | Active | Phase 3 | none listed |
| Levomenthol | Marketed | Phase 3 | none listed |
| AMG 333 | Stopped | Phase 1 | none listed |
| PF-05105679 | Status not established | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 4 |
| Engaged | 2 |
| Undetermined | 3 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Nihon Pharmaceutical | Route B |
| Alcon | Route B |
| Reckitt Benckiser | Route B |
The other 7 companies at TRPM8
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at TRPM8, ranked, with the facts behind eachRequest access. Nothing is shown until you do.